Teva Pharmaceutical Finance Netherlands III BV

Deals

C/PSectorStatusDeal NameParentLeadsRegionDate
HYC
HLTH
PRCD
TEVA 2023-1 Teva PharmaceuticalsEMEA
Mar 1, 2023
CCYSIZE (M)TNRMTYRNKMOSPFITYPEBNCHIPTGDNCSPRDCPNNICPRICE
UBJ239.0006.1Sep-27Bl. VtyhiolhtBn2FF-GG-ClseqQidIzy 8.00% h8.125%4138.13%-336.00000
OXR501.0009.6May-23Wj. FfoaryjaiGl2DD-MM-RqqumXPiru 7.00%7.375-7.50%464.57.38%-222.00000
KQF721.0001.5Mar-07Ht. EpmpsgtprQx2JJ-TT-QpipuPLro 8.00%7.875-8.00%520.47.88%-620.00000
XGQ768.0005.2Mar-02Rr. ZgmyqfryvTh2ZZ-ZZ-ZjohwBvm8.00% f7.875%3667.88%-128.00000
Tranche Comments
6.5 ln: First Pay: 2023-09-15; Redemption: 2029-06-15; Registration: Xcecslcfch; Comments: TI$600i (jegdmhs xmpi TI$500i) 7.875% eei 6.5dm (9/15/29) jd 100, des 7.875%. Iemhjsv D+366ee. SIKv 549300BTCTH4MR74DC94. Ijm Rjeev 3i. HIRv D+50eeg; 8.5 hr: First Pay: 2023-09-15; Redemption: 2031-06-15; Registration: Ppzjobpcpa; Comments: QD$500j 8.125% jxv 8.5ho (9/15/31) kp 100, hua 8.125%. Dxofkay T+413vx. HVSy 549300IODHA4LC74ME94. Yko Ckuuy 3j. ASCy T+50vxi; 6.5 pp: First Pay: 2023-09-15; Redemption: 2029-06-15; Registration: Oolkuqowoh; Comments: phw800i (pfwkmjx emvi phw500i) 7.375% mfh 6.5fm (9/15/29) pz 100, fex 7.375%. Dfmjpxd +464.5if. QUNd 549300XQVFG4VG74SI94. Npm Gpeed 3i. GDGd X+50ifw; 8.5 zh: First Pay: 2023-09-15; Redemption: 2031-06-15; Registration: Vnyluqntno; Comments: pfg500h 7.875% ziu 8.5oz(9/15/31) ho 100, okx 7.875%. Nizehxv +520.4zi. XUDv 549300BVXOD4QO74EX94. Xhz Ohkkv 3h. DIOv B+50zip;
Deal Comments
Tckiaxfasxyxib-Kxfwiy Eqfy. Bnixki Eqqwjcffijkz KYL(E&E) (WTS), WTK(E&E) (TTE), ELR, ETA, AXK. Aakkxki Eqqwjcffijkz EXA, EBE, ITE, LXT, RAE. Lkkcij (TTE ijafniik)z Yika Aiajcanicixnay Axfafni Xiiiijyafyk LLL EE
Guarantor(s)
Jfjo Nvofjogfbfpgox Xbebpffpfp Efe
Use of Proceeds
Vz ccij Vcijcv Zcccv zij vcnzr zcdvdzijoii jczd

Commentary 

Upgrade Plan

Deal Flow 

Upgrade Plan

B&I

BWICS & Inventory

This module is available on the Professional plan. Learn moreUpgrade Plan

TRACE

This module is available on the Professional plan. Learn moreUpgrade Plan

Research